Your session is about to expire
← Back to Search
Double-blind Treatment (DBT) Period: ACU193 35 mg/kg for Alzheimer's Disease (ALTITUDE-AD Trial)
ALTITUDE-AD Trial Summary
This trial aims to test if ACU193 infusions given every four weeks can help slow down mental and physical decline in people with early Alzheimer's disease compared to a placebo.
ALTITUDE-AD Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ALTITUDE-AD Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the current enrollment size of participants for this research?
"For the successful completion of this research, a total of 2040 eligible individuals are needed. Acumen Pharmaceuticals, the trial sponsor, will oversee operations at various locations such as Hôpital de la Timone in Marseille Cedex 05 and Institut de la Mémoire et de la Maladie d'Alzheimer - IM2A in Paris, Lanarkshire."
In how many medical facilities is this examination being conducted?
"The trial is being conducted at Hôpital de la Timone in Marseille Cedex 05, California; Institut de la Mémoire et de la Maladie d'Alzheimer - IM2A in Paris, Lanarkshire; and K2 Medical Research - Villages in Lady Lake, Barcelona. Additionally, there are another 126 sites involved in this study."
Does this study include individuals who are older than 70 years?
"Individuals aged between 50 and 90 are eligible for enrollment in this study. It is noteworthy that there are 14 trials catering to those under 18 years old and a substantial number of 535 trials focusing on individuals older than 65."
Are potential participants currently able to apply for enrollment in this study?
"Indeed, information on clinicaltrials.gov affirms the ongoing recruitment status of this investigation. Originally listed on February 29th, 2024, and last revised on March 21st, 2024, the study aims to enroll a substantial cohort of 2040 participants across an extensive network of 126 institutions."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger